• Modeling strict age-targeted mitigation strategies for COVID-19 (link)
  • Jaap van DisselRIVM -Technical briefing to Parliament –22 april 20201COVID-19Technical briefing To Parliament22 april 2020 (link)
  • COVID-19-EPIDEMIC :The role of children in the transmission of SARS-CoV-2 (COVID-19) – a rapid review (link)
  • COVID-19 in children and the role of schoolsettings in COVID-19 transmission (link)
  • Limited Secondary Transmission of SARS-CoV-2 in Child Care Programs — Rhode Island, June 1–July 31, 2020 (link)
  • Children are not COVID-19 super spreaders: time to go back to school (link)
  • No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020 (link)
  • COVID-19 Transmission and Children: The Child Is Not to Blame (link)
  • Transmission dynamics of SARS‐CoV‐2 within families with children in Greece: A study of 23 clusters (link)
  • Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020 (link)
  • Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic (link)
  • Evaluation of the virulence of SARS-CoV-2 in France, from all-cause mortality 1946-2020 (link)
  • French study finds anti-malarial and antibiotic combo could reduce COVID-19 duration (link)
  • Viral dynamics in mild and severe cases of COVID-19 (link)
  • Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19)
  • People ‘shed’ high levels of coronavirus, study finds, but most are likely not infectious after recovery begins (link)
  • Data Guide for Parameter Estimates List of Parameters (link)
  • Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study (link)
  • Coronavirus: Why You Must Act Now (link)
  • An Effective Treatment for Coronavirus (COVID-19) (link)
  • Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand (link)
  • Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) (link)
  • Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study (Link)
  • Second dog tests positive for coronavirus in Hong Kong days after the first to contract the disease died (Note there is no evidence of wide spread through the canine population - Daily Mail)
  • Why the Coronavirus Has Been So Successful - We’ve known about SARS-CoV-2 for only three months, but scientists can make some educated guesses about where it came from and why it’s behaving in such an extreme way.

 

  •  German study shows low coronavirus infection rate in schools (link)
  • COVID-19 - research evidence summaries (link)
  • PCR and Serological Studies (link)

This is a thread on use of drugs for COVID19

Hydroxychloroquine (Lupus, RA) Lopinavir/Ritonavir (HIV/AIDS) Remdisivir and Favipiravir (Ebola) and Camostat (Pancreatitis, Japan) are drugs that seem to have activity against SARSCov2 Some of these are used on Emergency Basis. Hydroxychloroquine is widely used for Rheumatoid Arthritis and Lups with good safety margin. It is similar to chloroquine without antimalarial activity. It is also safer than Chloroquine. It inhibits many enveloped viruses including Coronavirus and Ebola. Hydroxychloroquine has superior activity against coronavirus compared to Chloroquine in concentrations achievable in practice. 400 mg Twice Daily for 1 day 400m daily for 6 days 5-6 mg/day maintenance would be sufficient. Although there are no trials proving Hydroxychloroquine efficacy, it is being used where no other treatments are available for prophylaxis among medical personnel.